Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630 drug, for which is in Phase II clinical trial. It is also developing SNP-810 is in phase II clinical trial for use in Pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. The company was founded in 2014 and is based in Taipei City, Taiwan.
Metrics to compare | 6634 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6634PeersSector | |
---|---|---|---|---|
P/E Ratio | −25.9x | −15.1x | −0.5x | |
PEG Ratio | −1.86 | 0.11 | 0.00 | |
Price/Book | 3.3x | 2.3x | 2.6x | |
Price / LTM Sales | - | 5.6x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 43.5% | |
Fair Value Upside | Unlock | −6.4% | 6.9% | Unlock |